MedAvail (MDVL)

Take Impact Assessment

Impact Scorecard
About

Overall impact

B (77)

Commentary

MedAvail is a strong overall performer. With a 'B' rating of 77.3 for overall impact (92nd percentile compared to all companies), MedAvail ranks 4th out of 33 industry peers, behind Adamas Pharmaceuticals, Biofarma and Doc Generici, and ahead of Zoetis, Ironwood Pharmaceuticals, Zynerba Pharmaceuticals and 26 others. On top material causes for MedAvail's industry (Pharmaceuticals & Biotech), MedAvail performs well in Child and Maternal Health (95.4 score), Humane Treatment of Animals (96.2), Disease Eradication (96.4) and 7 other causes where it received an 'A' score and performs poorly in Technology Innovation (21.9 score) and Reduced Green House Gas Emissions (25.6).

... read full commentary

Screens

Advertising
Alcohol
Alcohol - responsible marketing
Animal treatment
Anti-abortion support
Anti-Israel
Anti-personnel mines
Arctic drilling
Banned pesticides and chemicals
Biological and chemical weapons
Cannabis
Carbon emissions intensity
Child safety
Cluster munitions
Coal
Contraceptives
Controversial weapons
Deforestation - financing
Deforestation - supply chain
Depleted uranium
Discrimination controversies
Electrical utility
Endangered wildlife
Environmental controversies
EU sanctions list
Factory farming
Fast food
Firearms
Food commodity derivatives
For-profit health care
Fossil fuel
Fur
Gambling
Genetic engineering
Health-related controversies
Human rights controversies
Human trafficking
ILO Conventions
Interest-based products
Interest-bearing debt
Interest-bearing securities
Iran
Land use and biodiversity
Military contracting
Misleading communication
Modern slavery
Music
Myanmar
Non-sustainable palm oil
Norges Bank exclusion list
Northern Ireland (Macbride)
North Korea
No SBTI commitment
Nuclear
OECD Guidelines
Oil and gas
Opioid controversies
Oppressive governments
Palestinian human rights
Pharma controversies
Pork
Pornography
Predatory lending
Prison involvement
Privacy breaches
Pro-life
Russia
Single-use plastic
Stem cell research
Sudan
Sugar
Syria
Tar sands
Thermal coal
Tobacco
Tobacco - GICS
UK sanctions list
Undermining US elections
UN Global Compact
UN Guiding Principles
US OFAC sanctions list
Weapons

Impact

Cause			MDVL

Peer rank

Overall impact

Log in to view this information

Screens

Advertising
Alcohol
Alcohol - responsible marketing
Animal treatment
Anti-abortion support
Anti-Israel
Anti-personnel mines
Arctic drilling
Banned pesticides and chemicals
Biological and chemical weapons
Cannabis
Carbon emissions intensity
Child safety
Cluster munitions
Coal
Contraceptives
Controversial weapons
Deforestation - financing
Deforestation - supply chain
Depleted uranium
Discrimination controversies
Electrical utility
Endangered wildlife
Environmental controversies
EU sanctions list
Factory farming
Fast food
Firearms
Food commodity derivatives
For-profit health care
Fossil fuel
Fur
Gambling
Genetic engineering
Health-related controversies
Human rights controversies
Human trafficking
ILO Conventions
Interest-based products
Interest-bearing debt
Interest-bearing securities
Iran
Land use and biodiversity
Military contracting
Misleading communication
Modern slavery
Music
Myanmar
Non-sustainable palm oil
Norges Bank exclusion list
Northern Ireland (Macbride)
North Korea
No SBTI commitment
Nuclear
OECD Guidelines
Oil and gas
Opioid controversies
Oppressive governments
Palestinian human rights
Pharma controversies
Pork
Pornography
Predatory lending
Prison involvement
Privacy breaches
Pro-life
Russia
Single-use plastic
Stem cell research
Sudan
Sugar
Syria
Tar sands
Thermal coal
Tobacco
Tobacco - GICS
UK sanctions list
Undermining US elections
UN Global Compact
UN Guiding Principles
US OFAC sanctions list
Weapons

Impact trend

Change in rating for overall impact

Log in to view this information

Company

Employees

279

Sector

Health Care

Industry

Pharmaceuticals

Sub-industry

Pharmaceuticals

SASB industry

Biotechnology & Pharmaceuticals

Headquarters

Az, United States

Share classes

MDVL

More info

https://medavail.com

Description

MedAvail Holdings, Inc., a technology-enabled retail pharmacy technology and services company, develops and commercializes self-service pharmacy, mobile application, and kiosk solutions in the United States and Canada. It offers a pharmacy technology solution, including the MedAvail MedCenter, which enables on-site pharmacy in medical clinics, retail store locations, employer sites with and without onsite clinics, and other locations where onsite prescription dispensing is desired. The MedAvail MedCenter also establishes an audio-visual connection to a live pharmacist, enabling prescription drug dispensing to occur directly to a patient with real-time supervision by a pharmacist. The company is headquartered in Phoenix, Arizona. On February 2, 2024, MedAvail Holdings, Inc. along with its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

Material causes

Ethos considers the following causes material for MedAvail, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

Access to affordable healthcare

Ensure universal access to affordable, quality healthcare

Accountable institutions

Build accountable and inclusive institutions at all levels

Child and maternal health

End preventable deaths of mothers and children, support reproductive health everywhere

Decent, safe work opportunities

Promote full and productive employment for all, in safe work environments

Disaster readiness and effective aid

Be prepared for natural disasters and provide effective aid when disasters happen

Disease eradication

Eradicate infectious and non-communicable diseases